1

Genocea Biosciences

#7287

Rank

$5.88K

Marketcap

US United States

Country

Genocea Biosciences
Leadership team

Mr. William D. Clark M.B.A. (Pres, CEO & Director)

Dr. Jessica Baker Flechtner Ph.D. (Chief Scientific Officer)

Ms. Diantha Duvall CPA, M.B.A. (CFO & Sec.)

Products/ Services
Biotechnology, Medical
Number of Employees
50 - 100
Headquarters
Cambridge, Massachusetts, United States
Established
2006
Company Registration
SEC CIK number: 0001457612
Revenue
500K - 2M
Traded as
GNCA
Social Media
Overview
Location
Summary
Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts.
History

Genocea Biosciences, Inc. was founded in 2013 as a biopharmaceutical company focusing on the development of new drugs that utilize the body's natural anti-inflammatory and anti-cancer defense mechanisms. The company has developed the PENTARAY Target Discovery Platform, which can access the pool of epitopes recognized by the human immune system to select multiple therapeutic targets for its candidate vaccines and for inhibiting T-cell disfunction associated with infectious diseases.

Mission
Our mission is to create innovative immunotherapeutics to fight cancer and infectious disease by leveraging powerful insights into the biology of the human immune system.
Vision
Our vision is to make a difference for patients by providing treatments that save and improve lives.
Key Team

Mr. William D. Clark M.B.A. (Pres, CEO & Director)

Dr. Jessica Baker Flechtner Ph.D. (Chief Scientific Officer)

Ms. Diantha Duvall CPA, M.B.A. (CFO & Sec.)

Recognition and Awards
2018 Frost & Sullivan Technology Innovation Leadership Award
References
Genocea Biosciences
Leadership team

Mr. William D. Clark M.B.A. (Pres, CEO & Director)

Dr. Jessica Baker Flechtner Ph.D. (Chief Scientific Officer)

Ms. Diantha Duvall CPA, M.B.A. (CFO & Sec.)

Products/ Services
Biotechnology, Medical
Number of Employees
50 - 100
Headquarters
Cambridge, Massachusetts, United States
Established
2006
Company Registration
SEC CIK number: 0001457612
Revenue
500K - 2M
Traded as
GNCA
Social Media